down arrow

KALA BIO, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4831192020
USD
0.96
-0.14 (-12.36%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.961.72

52 Week

0.6120.60
Valuation
Technical
Day's Volume

CASH

10.0 M

Shareholding (Mar 2025)

FII

0.05%

Held by 10 FIIs

DII

86.51%

Held by 4 DIIs

Promoter

9.83%

How big is KALA BIO, Inc.?

22-Jun-2025

As of Jun 18, KALA BIO, Inc. has a market capitalization of 26.97 million and reported net sales of 0.00 million with a net profit of -35.66 million over the last four quarters. Shareholder's funds are 12.33 million, and total assets amount to 55.48 million.

As of Jun 18, KALA BIO, Inc. has a market capitalization of 26.97 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters. During the same period, the consolidated net profit was -35.66 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 12.33 million and total assets amounting to 55.48 million.

Read More

What does KALA BIO, Inc. do?

22-Jun-2025

KALA BIO, Inc. is a biopharmaceutical company specializing in developing therapeutics for eye diseases using its nanoparticle-based technology. It has a market cap of approximately $26.97 million and reported a net profit loss of $9 million as of March 2025.

Overview:<BR>KALA BIO, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics using its nanoparticle-based Mucus Penetrating Particles technology, primarily targeting eye diseases. It operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 26.97 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.96<BR>Return on Equity: -617.36%<BR>Price to Book: 4.73<BR><BR>Contact Details:<BR>Address: 490 ARSENAL WAY, SUITE 120, WATERTOWN MA: 02472<BR>Tel: ['1 781 9965252', '1 212 3621200']<BR>Fax: 1 781 6420399<BR>Website: http://kalarx.com/

Read More

Who are in the management team of KALA BIO, Inc.?

22-Jun-2025

As of March 2022, KALA BIO, Inc.'s management team includes Mr. Mark Iwicki as Chairman, President, and CEO, with Mr. Andrew Koven as Lead Independent Director and independent directors Dr. Gregory Grunberg, Mr. Robert Paull, Mr. Gregory Perry, and Mr. Howard Rosen.

As of March 2022, the management team of KALA BIO, Inc. includes Mr. Mark Iwicki, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Andrew Koven as the Lead Independent Director, along with independent directors Dr. Gregory Grunberg, Mr. Robert Paull, Mr. Gregory Perry, and Mr. Howard Rosen.

Read More

Is KALA BIO, Inc. overvalued or undervalued?

25-Jun-2025

As of August 4, 2023, KALA BIO, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a Price to Book Value of 4.68 and a ROE of -617.36%, significantly underperforming its peers and the S&P 500.

As of 4 August 2023, KALA BIO, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently overvalued, as evidenced by its Price to Book Value of 4.68, a negative EV to EBITDA of -0.40, and an alarming ROE of -617.36%. These figures suggest that the company is struggling financially and is not generating positive returns for its shareholders.<BR><BR>In comparison to its peers, KALA BIO, Inc. has a less favorable position, with Regulus Therapeutics, Inc. showing a P/E ratio of -11.9462 and an EV to EBITDA of -9.7830, while Cumberland Pharmaceuticals, Inc. is rated risky with a P/E of -21.9132. The stark differences in these ratios highlight KALA's relative weakness in the market. Furthermore, KALA BIO's stock has significantly underperformed against the S&P 500, with a year-to-date return of -42.07% compared to the index's 2.44%.

Read More

Is KALA BIO, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, KALA BIO, Inc. shows a bullish technical trend with strong indicators, despite some bearish RSI readings, and has significantly outperformed the S&P 500 with a 1-month return of 104.37% and a 1-year return of 202.33%.

As of 20 August 2025, the technical trend for KALA BIO, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view, particularly in the daily moving averages and the weekly KST and OBV, both of which are bullish. However, the weekly and monthly RSI readings are bearish, suggesting some caution. The Bollinger Bands indicate a bullish stance on the monthly timeframe. <BR><BR>In terms of performance, KALA BIO has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 104.37% compared to the S&P 500's 2.33%, and a 1-year return of 202.33% versus 17.14%. Overall, the strength of the bullish trend is supported by the recent price action and strong returns relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 102 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.01

stock-summary
Return on Equity

1,142.64%

stock-summary
Price to Book

-31.71

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-93.58%
0%
-93.58%
6 Months
-76.43%
0%
-76.43%
1 Year
-85.26%
0%
-85.26%
2 Years
-84.14%
0%
-84.14%
3 Years
-80.8%
0%
-80.8%
4 Years
-98.88%
0%
-98.88%
5 Years
-99.74%
0%
-99.74%

KALA BIO, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is KALA BIO, Inc. technically bullish or bearish?

As of 20 August 2025, the technical trend for KALA BIO, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view, particularly in the daily moving averages and the weekly KST and OBV, both of which are bullish. However, the weekly and monthly RSI readings are bearish, suggesting some caution. The Bollinger Bands indicate a bullish stance on the monthly timeframe. In terms of performance, KALA BIO has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 104.37% compared to the S&P 500's 2.33%, and a 1-year return of 202.33% versus 17.14%. Overall, the strength of the bullish trend is supported by the recent price action and strong returns relative to the benchmark....

Read More
KALA BIO, Inc. Hits New 52-Week High of $20.60

KALA BIO, Inc. Hits New 52-Week High of $20.60

KALA BIO, Inc. has achieved a new 52-week high, reflecting significant growth over the past year. The company has outperformed the S&P 500 and boasts a notable return on equity, despite being unprofitable. With a market capitalization of USD 102 million, it maintains a balanced capital structure.

Read More
KALA BIO, Inc. Hits New 52-Week High of $20.12, Up 195% Year-Over-Year

KALA BIO, Inc. Hits New 52-Week High of $20.12, Up 195% Year-Over-Year

KALA BIO, Inc. has achieved a new 52-week high of USD 20.12, reflecting a substantial increase in stock performance over the past year. With a market capitalization of USD 102 million, the company operates in the Pharmaceuticals & Biotechnology sector and has demonstrated remarkable profitability metrics despite currently being loss-making.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
8.63%
EBIT to Interest (avg)
-10.09
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.96
Sales to Capital Employed (avg)
0.03
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
72.69%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.68
EV to EBIT
-0.39
EV to EBITDA
-0.40
EV to Capital Employed
-2.82
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-617.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 4 Schemes (3.61%)

Foreign Institutions

Held by 10 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -25.84% vs -8.54% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.80",
          "val2": "-10.60",
          "chgp": "-1.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "1.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-8.90",
          "chgp": "-25.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.77% vs 5.80% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-40.20",
          "val2": "-38.90",
          "chgp": "-3.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.80",
          "val2": "5.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.50",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.50",
          "val2": "-42.20",
          "chgp": "8.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.80
-10.60
-1.89%
Interest
1.10
1.10
Exceptional Items
-0.20
-0.00
Consolidate Net Profit
-11.20
-8.90
-25.84%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -25.84% vs -8.54% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-40.20
-38.90
-3.34%
Interest
5.80
5.80
Exceptional Items
-0.50
-0.50
Consolidate Net Profit
-38.50
-42.20
8.77%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.77% vs 5.80% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About KALA BIO, Inc. stock-summary
stock-summary
KALA BIO, Inc.
Pharmaceuticals & Biotechnology
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Company Coordinates stock-summary
Company Details
490 ARSENAL WAY, SUITE 120 , WATERTOWN MA : 02472
stock-summary
Tel: 1 781 99652521 212 3621200
stock-summary
http://kalarx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."